Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
CME Available: https://auau.auanet.org/node/33260 ACKNOWLEDGEMENTS Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
▶︎
Genetic Testing in Advanced Prostate Cancer
▶︎
Manipulating the Androgen Axis: Androgen Receptor Pathway Inhibitors in HSPC and CRPC (2026)
▶︎
Targeting the Androgen Receptor: Past, Present and Future
▶︎
Addiction Neuroscience 101
▶︎
Chemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRI
▶︎
How AI Cracked the Protein Folding Code and Won a Nobel Prize
▶︎
AR V7 Predicts Response in CRPC
▶︎
Identification of High Risk Disease and Initial Management of Biochemical Recurrence
▶︎
The Gillett Health Podcast: Androgen Receptors, L-Carnitine, Heat Shock Proteins, & More
▶︎
Evolving Strategies in the Diagnosis and Treatment of Muscle-Invasive Bladder Cancer
▶︎
Functional mapping of androgen receptor activity
▶︎
ADD/ADHD | What Is Attention Deficit Hyperactivity Disorder?
▶︎
Grand Rounds Emergency Medicine: Immunotherapy for B cell Lymphoproliferative Disorders (5/26/26)
▶︎
Localized Prostate Cancer: Androgen Deprivation Therapy (ADT) - 2021 Prostate Cancer Conference
▶︎
The Most Misunderstood Concept in Physics
▶︎
M1 CRPC: First and Second Line Treatment Options (2026)
▶︎
NMIBC Tumor Board: Nuances in Management w/ Dr. Mark Tyson & Dr. Sarah Psutka | Tumor Board Ep. 30
▶︎
SABCS 2021: A new perspective on androgen receptor action in estrogen receptor-α positive breast ...
▶︎
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
▶︎